Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Greinix, HT.
DLI or second transplant.
Ann Hematol. 2002; 81 Suppl 2(5):S34-S35
Web of Science
PubMed
- Führende Autor*innen der Med Uni Graz
- Greinix Hildegard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Abstract:
- We analyzed toxicity and efficacy of second allogeneic hematopoietic stem cell transplantation (HSCT) or donor lymphocyte infusions (DLI) in 66 patients relapsing with acute myeloid leukemia (n = 15), acute lymphoblastic leukemia (n = 5), chronic myeloid leukemia (n = 14), non-Hodgkin's lymphoma (n = 14), myeloma (n = 8), myelodysplastic syndrome (n = 8), and metastatic renal cell carcinoma (n = 2). Forty-one patients were given second HSCT and 25 DLI. Sixteen patients (39%) are alive and disease-free after a second HSCT including 13 who had received nonmyeloablative conditioning. Thirteen patients (52%) are alive after DLI with mainly chronic myeloid leukemia patients in continuous complete remission. Relapse after HSCT is still a challenging situation and further studies to improve outcome of these patients are warranted.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Blood Donors -
- Carcinoma, Renal Cell - therapy
- Female -
- Hematopoietic Stem Cell Transplantation - mortality
- Humans -
- Kidney Neoplasms - therapy
- Leukemia - therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy
- Leukemia, Myeloid, Acute - therapy
- Lymphocyte Transfusion -
- Lymphoma, Non-Hodgkin - therapy
- Male -
- Middle Aged -
- Multiple Myeloma - therapy
- Myelodysplastic Syndromes - therapy
- Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
- Recurrence -
- Treatment Outcome -